Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis.
Previous studies have found that telomerase reverse transcriptase (TERT) has vital roles in the development of malignant diseases including glioma. The occurrence of TERT promoter mutations in gliomas is frequent. So far, several studies on the association between TERT promoter mutations and prognosis of gliomas had been published, but the conclusion was still not uncertain. The aim of the present meta-analysis was to assess the association between TERT promoter mutations and survival of glioma patients by pooling data from published studies. PubMed, Embase, and Web of Science were searched for articles on the association between TERT promoter mutations and survival of glioma patients until June 30, 2015. Hazard ratios (HR) and the 95% confidence intervals (CIs) were utilized to analyze the prognosis of glioma patients with TERT promoter mutations. Heterogeneity of included studies was assessed using Cochrane's Q test and I (2) method. Eleven studies with a total of 3,444 glioma patients were finally included into the meta-analysis. Nine studies reported the HRs adjusting for other confounding factors. Meta-analysis of total 11 studies suggested that TERT promoter mutations were significantly associated with worse prognosis of patients with gliomas (HR = 2.07, 95% CI = 1.58-2.71, P < 0.00001). Meta-analysis of nine studies with adjusted outcomes suggested that TERT promoter mutations were independently associated with worse prognosis of patients with gliomas (HR = 2.28, 95% CI = 1.72-3.01, P < 0.00001). In conclusion, TERT promoter mutation is a promising biomarker for predicting worse prognosis for patients with gliomas. More prospective well-designed cohort studies are needed to further validate its prognostic role in gliomas.
Department of Neurosurgery, General Hospital of Shenyang Military Area Command, Shenyang, 110840, China.
Xiaogang
X
Wang
Department of Neurosurgery, General Hospital of Shenyang Military Area Command, Shenyang, 110840, China.
Xiaoming
X
Li
Department of Neurosurgery, General Hospital of Shenyang Military Area Command, Shenyang, 110840, China.
Feng
F
Xu
Department of Neurosurgery, General Hospital of Shenyang Military Area Command, Shenyang, 110840, China.
Youqian
Y
Zhang
Department of Neuroscience, Xiangya Hospital, Central South University, Changsha, 410008, China.
Hongwei
H
Liu
Department of Neurosurgery, General Hospital of Shenyang Military Area Command, Shenyang, 110840, China. csuxyl@tom.com.
Yingqun
Y
Tao
D000328:Adult; D001932:Brain Neoplasms / Q000201:enzymology* / Q000235:genetics*; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005910:Glioma / Q000201:enzymology* / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D011379:Prognosis; D011401:Promoter Regions, Genetic; D016019:Survival Analysis; D019098:Telomerase / Q000235:genetics*; D055815:Young Adult
C509186:TERT protein, human; D019098:Telomerase
Gliomas; Survival; TERT promoter mutation